Crohn's fistula study looks back at MRI changes, not forward to new treatments
NCT ID NCT07152977
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked back at 52 Crohn's disease patients with anal fistulas who were treated with biotherapy (infliximab, adalimumab, ustekinumab, or vedolizumab). Researchers compared their MRI scans at the start of treatment and during follow-up to see how the fistulas changed over time. The goal was simply to describe these radiological changes, not to test a new drug or treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANOPERINEAL LESIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Rouen Hospital
Rouen, 76031, France